Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. Uemura T, et al. Cancer Med. 2023 Dec;12(23):21097-21110. doi: 10.1002/cam4.6668. Epub 2023 Nov 10. Cancer Med. 2023. PMID: 37948122 Free PMC article.
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Miyawaki T, Kenmotsu H, Harada H, Ohde Y, Chiba Y, Haratani K, Okimoto T, Sakamoto T, Wakuda K, Ito K, Uemura T, Sakata S, Kogure Y, Nishimura Y, Nakagawa K, Yamamoto N. Miyawaki T, et al. Among authors: uemura t. BMC Cancer. 2021 Oct 18;21(1):1121. doi: 10.1186/s12885-021-08851-z. BMC Cancer. 2021. PMID: 34663250 Free PMC article. Clinical Trial.
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, Itoh S, Uemura T, Morinaga R, Takahama T, Nakashima K, Tachihara M, Saito G, Tanizaki J, Otsubo K, Ikeda S, Matsumoto H, Hara S, Hata A, Masuda T, Yamamoto N. Fujimoto D, et al. Among authors: uemura t. JTO Clin Res Rep. 2021 Dec 16;3(2):100265. doi: 10.1016/j.jtocrr.2021.100265. eCollection 2022 Feb. JTO Clin Res Rep. 2021. PMID: 35146460 Free PMC article.
Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study.
Hasegawa T, Okuyama T, Uemura T, Matsuda Y, Otani H, Shimizu J, Horio Y, Watanabe N, Yamaguchi T, Fukuda S, Oguri T, Maeno K, Tamiya A, Nosaki K, Fukumitsu K, Akechi T. Hasegawa T, et al. Among authors: uemura t. Oncologist. 2022 Nov 3;27(11):982-990. doi: 10.1093/oncolo/oyac178. Oncologist. 2022. PMID: 36067268 Free PMC article.
Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.
Hasegawa T, Okuyama T, Uemura T, Matsuda Y, Otani H, Shimizu J, Horio Y, Watanabe N, Yamaguchi T, Fukuda S, Oguri T, Maeno K, Taniguchi Y, Nosaki K, Fukumitsu K, Akechi T. Hasegawa T, et al. Among authors: uemura t. Oncologist. 2024 Feb 2;29(2):e282-e289. doi: 10.1093/oncolo/oyad245. Oncologist. 2024. PMID: 37669003 Free PMC article.
Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Tasaki Y, Sugiyama Y, Hamamoto S, Naiki T, Uemura T, Yokota K, Kawakita D, Nakamura M, Ogawa R, Shimura T, Mimura Y, Hotta Y, Odagiri K, Ito N, Iida M, Kimura Y, Komatsu H, Kataoka H, Takiguchi S, Morita A, Iwasaki S, Okuda K, Niimi A, Yasui T, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: uemura t. Cancer Med. 2023 Dec;12(24):21666-21679. doi: 10.1002/cam4.6724. Epub 2023 Nov 21. Cancer Med. 2023. PMID: 37986680 Free PMC article.
1,444 results